Download PDF
Semin intervent Radiol 2019; 36(03): 279-284
DOI: 10.1055/s-0039-1694066
Trainee Corner
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Hepatocellular Carcinoma: Combined Transarterial Chemoembolization and Ablation

Josi L. Herren
1   Department of Radiology, University of Illinois College of Medicine, Chicago, Illinois
,
Nerina Disomma
1   Department of Radiology, University of Illinois College of Medicine, Chicago, Illinois
,
Charles E. Ray Jr.
1   Department of Radiology, University of Illinois College of Medicine, Chicago, Illinois
› Author Affiliations
Further Information

Publication History

Publication Date:
19 August 2019 (online)

Also available at
    Permissions and Reprints

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death. Transarterial chemoembolization (TACE) has become a mainstay for the treatment of large unresectable or multifocal HCCs that are not amenable to surgical resection. Additionally, ablation methods have been developed for patients with small HCCs who are not candidates for surgical resection or liver transplantation, and for patients with early stage HCC awaiting transplantation. The use of combined TACE and ablation can overcome the limitations when either is used alone, as well as conferring a survival benefit. The purpose of this article is to provide the trainee with a primer on the use of combined TACE ablation, including a literature review of combined therapy. Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and represents one of the leading causes of cancer-related death.[1] Additionally, liver cancer incidence has more than tripled since 1980.[2]

 

  • References

  • 1 U.S. Cancer Statistics Working Group. Available at: www.cdc.gov/cancer/USCS/about/index . Accessed July 26, 2019
    PubMed
  • 2 American Cancer Society. Available at: https://cancerstatisticscenter.cancer.org . Accessed July 19, 2019
    PubMed
  • 3 Vogl TJ, Naguib NN, Nour-Eldin NE. , et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int J Cancer 2012; 131 (03) 733-740
    CrossrefPubMedGoogle Scholar
  • 4 Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol 2011; 28 (Suppl. 01) S286-S290
    CrossrefPubMedGoogle Scholar
  • 5 Martin RC, Joshi J, Robbins K. , et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 2011; 18 (01) 192-198
    CrossrefPubMedGoogle Scholar
  • 6 Kobayashi K, Gupta S, Trent JC. , et al. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors. Cancer 2006; 107 (12) 2833-2841
    CrossrefPubMedGoogle Scholar
  • 7 Sato T, Eschelman DJ, Gonsalves CF. , et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2008; 26 (33) 5436-5442
    CrossrefPubMedGoogle Scholar
  • 8 Chen L, Zheng Y, Zhang H. , et al. Comparative analysis of tumor-associated vascular changes following TACE alone or in combination with sorafenib treatment in HCC: a retrospective study. Oncol Lett 2018; 16 (03) 3690-3698
    PubMedGoogle Scholar
  • 9 Li L, Zhao W, Wang M. , et al. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2018; 18 (01) 138
    CrossrefPubMedGoogle Scholar
  • 10 Brown DB, Cardella JF, Sacks D. , et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2006; 17 (2, Pt 1): 225-232
    CrossrefPubMedGoogle Scholar
  • 11 Brown DB, Nikolic B, Covey AM. , et al; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2012; 23 (03) 287-294
    CrossrefPubMedGoogle Scholar
  • 12 Raoul JL. Natural history of hepatocellular carcinoma and current treatment options. Semin Nucl Med 2008; 38 (02) S13-S18
    CrossrefPubMedGoogle Scholar
  • 13 American Cancer Society. Cancer Facts & Figures. 2016 . Available at: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf . Accessed June 25, 2017
    PubMedGoogle Scholar
  • 14 Flores A, Marrero JA. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol 2014; 8: 71-76
    PubMedGoogle Scholar
  • 15 Emami B, Lyman J, Brown A. , et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21 (01) 109-122
    PubMedGoogle Scholar
  • 16 Cárdenes HR, Price TR, Perkins SM. , et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010; 12 (03) 218-225
    CrossrefPubMedGoogle Scholar
  • 17 Bujold A, Massey CA, Kim JJ. , et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013; 31 (13) 1631-1639
    CrossrefPubMedGoogle Scholar
  • 18 Gaba RC, Lokken RP, Hickey RM. , et al; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy. J Vasc Interv Radiol 2017; 28 (09) 1210-1223.e3
    CrossrefPubMedGoogle Scholar
  • 19 Kis B, El-Haddad G, Sheth RA. , et al. Liver-directed therapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Contr 2017; 24 (03) 1073274817729244
    PubMedGoogle Scholar
  • 20 Kishore S, Friedman T, Madoff DC. Update on embolization therapies for hepatocellular carcinoma. Curr Oncol Rep 2017; 19 (06) 40
    CrossrefPubMedGoogle Scholar
  • 21 Xu HX, Lu MD, Xie XY. , et al. Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients. Clin Radiol 2005; 60 (09) 1018-1025
    CrossrefPubMedGoogle Scholar
  • 22 Rossi S, Garbagnati F, Lencioni R. , et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000; 217 (01) 119-126
    CrossrefPubMedGoogle Scholar
  • 23 Peng ZW, Zhang YJ, Chen MS. , et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31 (04) 426-432
    CrossrefPubMedGoogle Scholar
  • 24 Wang Y, Ma L, Sheng S, Yuan Z, Zheng J, Li W. Combination therapy of TACE and CT-guided partial hepatic segment ablation for liver cancer. Minim Invasive Ther Allied Technol 2018; 19: 1-10
    PubMedGoogle Scholar
  • 25 Chen QW, Ying HF, Gao S. , et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2016; 40 (03) 309-314
    CrossrefPubMedGoogle Scholar
  • 26 Ginsburg M, Zivin SP, Wroblewski K, Doshi T, Vasnani RJ, Van Ha TG. Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation. J Vasc Interv Radiol 2015; 26 (03) 330-341
    CrossrefPubMedGoogle Scholar
  • 27 Si ZM, Wang GZ, Qian S. , et al. Combination therapies in the management of large (≥ 5 cm) hepatocellular carcinoma: microwave ablation immediately followed by transarterial chemoembolization. J Vasc Interv Radiol 2016; 27 (10) 1577-1583
    CrossrefPubMedGoogle Scholar
  • 28 Xu LF, Sun HL, Chen YT. , et al. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol 2013; 28 (03) 456-463
    CrossrefPubMedGoogle Scholar
  • 29 Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2013; 19 (24) 3872-3882
    CrossrefPubMedGoogle Scholar
  • 30 Yan S, Xu D, Sun B. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci 2012; 57 (11) 3026-3031
    CrossrefPubMedGoogle Scholar
  • 31 Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2013; 139 (04) 653-659
    CrossrefPubMedGoogle Scholar
  • 32 Wang WD, Zhang LH, Ni JY. , et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization therapy versus surgical resection for hepatocellular carcinoma within the Milan criteria: a meta-analysis. Korean J Radiol 2018; 19 (04) 613-622
    CrossrefPubMedGoogle Scholar
  • 33 Yi PS, Huang M, Zhang M, Xu L, Xu MQ. Comparison of transarterial chemoembolization combined with radiofrequency ablation therapy versus surgical resection for early hepatocellular carcinoma. Am Surg 2018; 84 (02) 282-288
    PubMedGoogle Scholar
  • 34 Peng ZW, Zhang YJ, Chen MS. , et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31 (04) 426-432
    CrossrefPubMedGoogle Scholar
  • 35 Long J, Zheng JS, Sun B, Lu N. Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study. Hepatol Int 2016; 10 (01) 175-184
    CrossrefPubMedGoogle Scholar
  • 36 Thornton LM, Cabrera R, Kapp M, Lazarowicz M, Vogel JD, Toskich BB. Radiofrequency vs microwave ablation after neoadjuvant transarterial bland and drug-eluting microsphere chembolization for the treatment of hepatocellular carcinoma. Curr Probl Diagn Radiol 2017; 46 (06) 402-409
    CrossrefPubMedGoogle Scholar
  • 37 Hu H, Chen GF, Yuan W, Wang JH, Zhai B. Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis. Int J Hyperthermia 2018; 34 (08) 1351-1358
    CrossrefPubMedGoogle Scholar
  • 38 National Comprehensive Cancer Network. Hepatobiliary Cancers (Version 1. 2019). Available at: https://jnccn.org/view/journals/jnccn/17/4/article-p302 . Accessed July 26, 2019
    PubMed
  • 39 Roccarina D, Majumdar A, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. Cochrane Database Syst Rev 2017; 3: CD011649
    PubMedGoogle Scholar
  • 40 Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011; 3 (03) CD004787
    PubMedGoogle Scholar
  • 41 Marrero JA, Kulik LM, Sirlin CB. , et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68 (02) 723-750
    CrossrefPubMedGoogle Scholar